Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

25,200 signal articles · 242 in last 24h · 120,199 total before filter · latest 32m ago
242last 24h
1427last 7d
240● bullish (7d)
156● bearish (7d)
205publishers
AllMacro256Earnings538M&A101Regulatory19Product10Analyst21
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Coherent (COHR) Q3 Earnings Match Estimates
Zacks105d agoneutral
Coherent (COHR) Q3 Earnings Match Estimates

Coherent (COHR) delivered earnings and revenue surprises of +0.24% and +1.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
Simply Wall St.105d agoneutral
Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions

Bristol-Myers Squibb, NYSE:BMY, has launched a new patient-focused "Won't Lose" media campaign ahead of the FIFA World Cup 2026. The campaign highlights the company’s focus on breakthrough medicines and resilience in the fight against serious diseases. The initiative is set to run nationwide across digital and social platforms and will feature high profile sports personalities. Bristol-Myers Squibb, NYSE:BMY, is putting fresh attention on its brand with "Won't Lose," a broad media effort...

First Lumentum, Now Coherent. Why Earnings Aren’t Boosting the AI Laser Stock.
Barrons.com105d agoneutral
First Lumentum, Now Coherent. Why Earnings Aren’t Boosting the AI Laser Stock.

Coherent reported quarterly earnings that were in-line with Wall Street’s expectations, with gross margins increasing slightly. The optical networking company is benefiting from the artificial intelligence data center boom—but shares fell anyway. Coherent posted adjusted earnings of $1.41 a share for the fiscal third-quarter, compared to 91 cents a year ago and Wall Street’s $1.40 a share prediction.

Hecla (HL) Q3 2025 Earnings Call Transcript
Motley Fool105d agoneutral
Hecla (HL) Q3 2025 Earnings Call Transcript

Robert Krcmarov: Thank you, Mike, and good morning, everyone. Let me just start by reminding you why Hecla stands apart in the silver sector. As the oldest silver company on the New York Stock Exchange with a history dating back 134 years, we operate exclusively in the premier jurisdictions of the United States and Canada.

Investing.com105d agobearish
Snap falls 3% on in-line second quarter guidance

Investing.com - Snap Inc. (NYSE:SNAP) reported first quarter results that exceeded analyst expectations, but shares fell 3% as the company’s second quarter revenue guidance came in roughly in line with Wall Street estimates.

AppLovin Stock Jumps, Then Reverses, Following Q1 Results
Investor's Business Daily105d agoneutral
AppLovin Stock Jumps, Then Reverses, Following Q1 Results

AppLovin reported first-quarter results that beat top- and bottom-line expectations. AppLovin helps mobile app developers find new users and sell advertising in their apps. AppLovin expects sales of $1.93 billion, based on the midpoint of its guidance range.

SolarEdge Technologies Q1 Earnings Call Highlights
MarketBeat105d agoneutral
SolarEdge Technologies Q1 Earnings Call Highlights

SolarEdge Technologies (NASDAQ:SEDG) reported first-quarter 2026 results that management said showed continued progress in its push toward “profitable growth,” alongside product launches and efforts to expand market share across key regions. On the earnings call, CEO Shuki Nir said 2026 is a “year o

Recursion Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat105d agoneutral
Recursion Pharmaceuticals Q1 Earnings Call Highlights

Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President

Novavax Q1 Earnings Call Highlights
MarketBeat105d agoneutral
Novavax Q1 Earnings Call Highlights

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

One Stop Systems Q1 Earnings Call Highlights
MarketBeat105d agoneutral
One Stop Systems Q1 Earnings Call Highlights

One Stop Systems (NASDAQ:OSS) reported a strong start to 2026, posting significant year-over-year gains in both revenue and profitability as demand increased for its ruggedized, enterprise-class compute platforms across defense and commercial markets. Management also reaffirmed full-year guidance, c

DoorDash Stock Rallying After Q1 Earnings Beat
Investor's Business Daily105d agobullish
DoorDash Stock Rallying After Q1 Earnings Beat

DoorDash stock rallied late Wednesday after the food-delivery company reported first-quarter earnings that beat estimates despite revenue slightly below expectations. For the March-ended quarter, DoorDash earned 44 cents per share, up slightly from 42 cents a year earlier. Sales increased 33% to $4 billion, below analyst estimates of $4.2 billion.

Stock Surge on Robust Tech Earnings and US-Iran Peace Hopes
Barchart105d agobullish
Stock Surge on Robust Tech Earnings and US-Iran Peace Hopes

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +1.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.08%. June E-mini S&P futures (ESM26 ) rose +1.45%, and June E-mini Nasdaq futures...

Fluence Energy (NASDAQ:FLNC) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings, But Stock Soars 20.6%
StockStory105d agobullish
Fluence Energy (NASDAQ:FLNC) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings, But Stock Soars 20.6%

Electricity storage and software provider Fluence (NASDAQ:FLNC) missed Wall Street’s revenue expectations in Q1 CY2026, but sales rose 7.7% year on year to $464.9 million. On the other hand, the company’s full-year revenue guidance of $3.4 billion at the midpoint came in 1.1% above analysts’ estimates. Its GAAP loss of $0.16 per share was in line with analysts’ consensus estimates.

Novavax (NVAX) Q1 2026 Earnings Transcript
Motley Fool105d agoneutral
Novavax (NVAX) Q1 2026 Earnings Transcript

James Kelly: Good morning, and thank you for joining us today to discuss our first quarter 2026 financial results and operational highlights. The forward-looking statements in this presentation are only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

Disney earnings show consumers are 'full systems go,' says CIO
Reuters Videos105d agoneutralVIDEO
Disney earnings show consumers are 'full systems go,' says CIO

<body><p>STORY: Disney reported adjusted earnings-per-share of $1.57 and revenue of $25.2 billion ​for January through March. Analysts, on average, had expected adjusted EPS of $1.49 and revenue of $24.78 billion, according to LSEG.</p><p>"All three aspects of their business did extraordinary," said Weinand, referring to streaming, theme parks and merchandise.&nbsp;</p><p>"I don't know the last time you've been to a theme park, but it's $300 to get in the door, and it's about $1,000 per person by the time you've left," he said. "Add that to almost every single streaming service is increasing their subscription prices, and people are paying it."&nbsp;</p><p>While most of those consumers are in middle- or upper-income brackets, Weinand said lower-middle class&nbsp; consumers are also spending, but at "entry-level consumer goods stores."</p><p>"That's kind of why I still like a Ross Stores or a TJ Maxx," he said, noting that shares of Ross Stores are "up about 26% this year."</p></body>

Novavax (NVAX) Q2 2025 Earnings Transcript
Motley Fool105d agoneutral
Novavax (NVAX) Q2 2025 Earnings Transcript

Luis Sanay: Good morning, and thank you all for joining us today to discuss our second quarter 2025 financial results and operational highlights. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including, but not limited to, statements related to Novavax's corporate strategy and operating plans, its strategic priorities, its partnerships and expectations with respect to potential royalties, milestones and cost reimbursements, its expectations regarding manufacturing capacity, timing, production and delivery for its COVID-19 vaccine, the development of Novavax's clinical and preclinical product candidates, the timing and results of our clinical trials, including the Nuvaxovid post-marketing commitment study, full year 2025 financial guidance and revenue framework and Novavax's future financial or business performance.